Literature DB >> 1709863

Antibody specificity and immunoglobulin VH gene utilization of human monoclonal CD5+ B cell lines.

M E Schutte1, S B Ebeling, K E Akkermans, F H Gmelig-Meyling, T Logtenberg.   

Abstract

Human B lymphocytes that bear the CD5 antigen are relatively abundant in early ontogeny and comprise a small fraction of the B cell population in adults. The CD5 B cell subset has attracted much attention because of its possible involvement in autoimmune disease and certain B cell malignancies. To begin to understand the role of CD5 B cells in disease processes, we have generated a panel of ten human monoclonal B cell lines selected for expression of the CD5 antigen. These cell lines were obtained by Epstein-Barr virus transformation of B lymphocytes isolated from the spleen, liver and bone marrow of a 19-week-old fetus, from cord blood and from peripheral blood of healthy volunteers. In addition, one cell line was isolated from the spleen of a patient with chronic lymphocytic leukemia. Here, we describe the antibody and immunoglobulin VH gene repertoire of this panel of CD5 B cell lines. The results of these experiments show that (a) some but not all CD5 B cell lines secrete polyreactive antibodies that bind to a variety of self- and xenoantigens and (b) members of the small VH4, VH5 and VH6 gene families are overrepresented in this panel of cell lines. Nucleotide sequence analysis revealed the expression of VH gene elements that have been previously reported in the preimmune B cell repertoire, in CD5 B cell tumors and in polyreactive antibodies.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1709863     DOI: 10.1002/eji.1830210505

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  9 in total

1.  Hiding in plain sight: time to unlock autoimmune clues in human CD5+ B cells by using nextgen technology.

Authors:  Rizwan Ahmed; Zahra Omidian; Thomas Donner; Abdel Rahiam A Hamad
Journal:  Discov Med       Date:  2018-09       Impact factor: 2.970

2.  Molecular single-cell analysis reveals that CD5-positive peripheral blood B cells in healthy humans are characterized by rearranged Vkappa genes lacking somatic mutation.

Authors:  M Fischer; U Klein; R Küppers
Journal:  J Clin Invest       Date:  1997-10-01       Impact factor: 14.808

3.  Evidence that the V kappa III gene usage is nonstochastic in both adult and newborn peripheral B cells and that peripheral CD5+ adult B cells are oligoclonal.

Authors:  J C Weber; G Blaison; T Martin; A M Knapp; J L Pasquali
Journal:  J Clin Invest       Date:  1994-05       Impact factor: 14.808

4.  Immunoglobulin heavy chain gene expression in peripheral blood B lymphocytes.

Authors:  C Huang; A K Stewart; R S Schwartz; B D Stollar
Journal:  J Clin Invest       Date:  1992-04       Impact factor: 14.808

5.  Expansion of a B-lymphocyte clone producing IgM auto-antibodies encoded by a somatically mutated VHI gene in the spleen of an autoimmune patient.

Authors:  S Jahn; B Niemann; T Winkler; J R Kalden; R von Baehr
Journal:  Rheumatol Int       Date:  1994       Impact factor: 2.631

6.  The nature of the autoimmune antibody repertoire in human immunodeficiency virus type 1 infection.

Authors:  H J Ditzel; S M Barbas; C F Barbas; D R Burton
Journal:  Proc Natl Acad Sci U S A       Date:  1994-04-26       Impact factor: 11.205

7.  Immunoglobulin heavy chain variable region gene utilization by B cell hybridomas derived from rheumatoid synovial tissue.

Authors:  C M Brown; C Longhurst; G Haynes; C Plater-Zyberk; A Malcolm; R N Maini
Journal:  Clin Exp Immunol       Date:  1992-08       Impact factor: 4.330

8.  Anti-islet cell and anti-insulin antibody production by CD5+ and CD5- B lymphocytes in IDDM.

Authors:  A Muñoz; T Gallart; E F Usac; J Fernández-Alvarez; O Viñas; N Somoza; J Barceló; R Gomis
Journal:  Diabetologia       Date:  1995-01       Impact factor: 10.122

9.  Genetic analysis of self-associating immunoglobulin G rheumatoid factors from two rheumatoid synovia implicates an antigen-driven response.

Authors:  T Olee; E W Lu; D F Huang; R W Soto-Gil; M Deftos; F Kozin; D A Carson; P P Chen
Journal:  J Exp Med       Date:  1992-03-01       Impact factor: 14.307

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.